10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome - Seite 2

Nachrichtenquelle: globenewswire
15.09.2020, 14:00  |  101   |   |   

"With this new technology, we can better understand the mechanisms affected by the non-coding risk genetic variation across a wide range of neuropsychiatric diseases, including Alzheimer’s, Parkinson’s, Schizophrenia, bipolar disorder and major depression, along with different severity of neuropathology and clinical symptomatology," added Dr. Panagiotis Roussos, Associate Professor of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai. 

By using Chromium Single Cell Multiome ATAC + Gene Expression, researchers can: 

  • Deepen their characterization of cell types and states with linked transcriptional and epigenomic analyses
  • Discover cells with similar transcriptional profiles but functionally different chromatin landscapes
  • Combine discovery of regulatory elements with gene expression to explore gene regulatory interactions driving cell differentiation, development, and disease
  • Easily interpret epigenetic profiles with key expression markers 
  • Maximize insights from precious samples with multiple readouts from the same cell

Chromium Single Cell Multiome ATAC + Gene Expression is shipping to customers. To learn more, visit https://www.10xgenomics.com/products/single-cell-multiome-atac-plus-ge ....

About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 1,500 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 775 issued patents and patent applications.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology.  These forward-looking statements include statements regarding 10x Genomics, Inc.’s partnership activities, which involve risks and uncertainties that could cause 10x Genomics, Inc.’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.

Seite 2 von 3
10x Genomics Registered (A) Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome - Seite 2 Chromium Single Cell Multiome ATAC + Gene Expression brings together two methods to profile biological systems at single cell resolutionPLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) - 10x Genomics (Nasdaq: TXG) today announced it has begun …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel